KR20220100925A - Npy2 수용체 작용제 - Google Patents

Npy2 수용체 작용제 Download PDF

Info

Publication number
KR20220100925A
KR20220100925A KR1020227019823A KR20227019823A KR20220100925A KR 20220100925 A KR20220100925 A KR 20220100925A KR 1020227019823 A KR1020227019823 A KR 1020227019823A KR 20227019823 A KR20227019823 A KR 20227019823A KR 20220100925 A KR20220100925 A KR 20220100925A
Authority
KR
South Korea
Prior art keywords
ethoxy
acetamido
group
hpyy
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227019823A
Other languages
English (en)
Korean (ko)
Inventor
페터 빌헬름 헤벨
알베르트 브렌나우어
샬롯 스탈 마데센
쇠렌 융베 페데르센
슈테판 페터스
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베링거 인겔하임 인터내셔날 게엠베하 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Publication of KR20220100925A publication Critical patent/KR20220100925A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227019823A 2019-11-11 2020-11-09 Npy2 수용체 작용제 Pending KR20220100925A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19208394 2019-11-11
EP19208394.7 2019-11-11
PCT/EP2020/081513 WO2021094259A1 (en) 2019-11-11 2020-11-09 Npy2 receptor agonists

Publications (1)

Publication Number Publication Date
KR20220100925A true KR20220100925A (ko) 2022-07-18

Family

ID=68531488

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227019823A Pending KR20220100925A (ko) 2019-11-11 2020-11-09 Npy2 수용체 작용제

Country Status (20)

Country Link
US (3) US20210139548A1 (https=)
EP (1) EP4058047A1 (https=)
JP (2) JP7821393B2 (https=)
KR (1) KR20220100925A (https=)
CN (1) CN114641303A (https=)
AR (1) AR120440A1 (https=)
AU (1) AU2020384729A1 (https=)
CA (1) CA3156452A1 (https=)
CL (1) CL2022001227A1 (https=)
CO (1) CO2022006046A2 (https=)
CR (1) CR20220206A (https=)
DO (1) DOP2022000097A (https=)
EC (1) ECSP22037660A (https=)
IL (1) IL292601A (https=)
JO (1) JOP20220110A1 (https=)
MX (1) MX2022005661A (https=)
PE (1) PE20221168A1 (https=)
PH (1) PH12022551101A1 (https=)
TW (1) TWI864155B (https=)
WO (1) WO2021094259A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220206A (es) 2019-11-11 2022-06-16 Boehringer Ingelheim Int Agonistas del receptor npy2
JP7661478B2 (ja) * 2020-08-07 2025-04-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性ｎｐｙ２受容体アゴニスト
JP2025526148A (ja) * 2022-08-18 2025-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 長時間作用型ｇｌｐ－１／グルカゴン受容体アゴニスト及びｎｐｙ２受容体アゴニストを含む組合せ治療
CN120865433A (zh) * 2022-12-21 2025-10-31 勃林格殷格翰国际有限公司 Glp1/gip/npy2受体的三重激动剂
EP4670741A1 (en) 2023-04-28 2025-12-31 Pinotbio, Inc. ANTIBODY-DRUG CONJUGATE IN WHICH ONE OR MORE DRUG-BINDER CONJUGATES ARE LINKED TO AN ANTIBODY AND ITS PREPARATION METHOD

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053726A1 (en) 2003-11-25 2005-06-16 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
NZ579621A (en) 2004-02-11 2011-03-31 Amylin Pharmaceuticals Inc Hybrid polypeptides with selectable properties
EA011860B1 (ru) 2004-03-17 2009-06-30 7ТиЭм ФАРМА А/С Селективные агонисты рецептора y2 для терапевтического воздействия
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP2360180A3 (en) 2004-12-13 2012-02-08 Amylin Pharmaceuticals Inc. Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
CA2630649A1 (en) 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor-agonists
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2158214B1 (en) 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagon analogues
UA97707C2 (ru) 2007-11-14 2012-03-12 Амилин Фармасьютикалз, Инк. Способы лечения ожирения и заболеваний, расстройств, связанных с ожирением
FR2934058B1 (fr) 2008-07-15 2010-09-24 Centre Nat Rech Scient Dispositif de projection interferometrique a trois ouvertures pour produire une tache constituee de structures fines
EP2370462B1 (en) 2008-12-15 2014-07-16 Zealand Pharma A/S Glucagon analogues
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
ES2477880T3 (es) 2008-12-15 2014-07-18 Zealand Pharma A/S Análogos del glucagón
CN102282167B (zh) 2008-12-15 2014-08-13 西兰制药公司 胰高血糖素类似物
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
WO2011033068A1 (en) 2009-09-18 2011-03-24 Novo Nordisk A/S Long-acting y2 receptor agonists
EP2498800A1 (en) 2009-11-13 2012-09-19 Novo Nordisk A/S Long-acting y2 receptor agonists
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
US9169310B2 (en) 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
JP6121992B2 (ja) 2011-06-10 2017-04-26 ノヴォ ノルディスク アー／エス ポリペプチド
IN2014CN04401A (https=) 2011-12-23 2015-09-04 Zealand Pharma As
IN2014MN02304A (https=) 2012-05-03 2015-08-07 Zealand Pharma As
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AU2014261111B2 (en) 2013-05-02 2017-03-16 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
AR097701A1 (es) 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
PL3057984T3 (pl) 2013-10-17 2018-12-31 Zealand Pharma A/S Acylowane analogi glukagonu
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
CN105722854B (zh) 2013-11-14 2020-08-04 关键生物科学有限公司 用于治疗疾病和病症的降钙素模拟物
EP3068795B1 (en) * 2013-11-15 2019-03-06 Novo Nordisk A/S Hpyy(1-36) having a beta-homoarginine substitution at position 35
CN105722526B (zh) * 2013-11-15 2020-12-08 诺和诺德股份有限公司 选择性pyy化合物及其用途
BR112017019378A2 (pt) 2015-03-18 2019-02-19 Zealand Pharma A/S análogos de amilina
DK3283507T3 (da) 2015-04-16 2020-01-02 Zealand Pharma As Acyleret glucagonanalog
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TWI694082B (zh) * 2015-06-12 2020-05-21 丹麥商諾佛 儂迪克股份有限公司 選擇性ｐｙｙ化合物及其用途
SG11201805586SA (en) 2015-12-31 2018-07-30 Hanmi Pharmaceutical Co Ltd Triple glucagon/glp-1/gip receptor agonist
EP3452088A4 (en) 2016-05-03 2020-04-15 The Scripps Research Institute TRKB AGONIST ANTIBODIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
JOP20190095A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
AR110300A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
CN108289005B (zh) 2017-01-09 2021-06-29 中兴通讯股份有限公司 信令发送、接收方法及装置
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
GB201720188D0 (en) 2017-12-04 2018-01-17 Imperial Innovations Ltd Analogues of PYY
US10581312B2 (en) 2017-12-29 2020-03-03 Texas Instruments Incorporated Multilevel converter using node voltage track and control
WO2019147650A1 (en) 2018-01-23 2019-08-01 Gila Therapeutics, Inc. Peptide yy pharmaceutical formulations, compositions, and methods
TWI847981B (zh) 2018-04-25 2024-07-11 比利時商健生藥品公司 類升糖素肽1 (glp-1)融合肽偶合環狀酪酪肽接合物及其用途
TW202535916A (zh) * 2018-11-01 2025-09-16 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
CR20220206A (es) 2019-11-11 2022-06-16 Boehringer Ingelheim Int Agonistas del receptor npy2
JP7661478B2 (ja) 2020-08-07 2025-04-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性ｎｐｙ２受容体アゴニスト

Also Published As

Publication number Publication date
US20210139548A1 (en) 2021-05-13
JP2023500895A (ja) 2023-01-11
AU2020384729A1 (en) 2022-04-14
TWI864155B (zh) 2024-12-01
AR120440A1 (es) 2022-02-16
JOP20220110A1 (ar) 2023-01-30
CO2022006046A2 (es) 2022-05-20
TW202134263A (zh) 2021-09-16
CR20220206A (es) 2022-06-16
JP7821393B2 (ja) 2026-02-27
ECSP22037660A (es) 2022-06-30
JP2026026081A (ja) 2026-02-16
PE20221168A1 (es) 2022-07-25
PH12022551101A1 (en) 2023-11-13
US12559529B2 (en) 2026-02-24
EP4058047A1 (en) 2022-09-21
CL2022001227A1 (es) 2023-02-03
US20230340039A1 (en) 2023-10-26
US12054525B2 (en) 2024-08-06
US20250002544A1 (en) 2025-01-02
IL292601A (en) 2022-07-01
MX2022005661A (es) 2022-09-07
DOP2022000097A (es) 2022-06-15
WO2021094259A1 (en) 2021-05-20
CA3156452A1 (en) 2021-05-20
CN114641303A (zh) 2022-06-17

Similar Documents

Publication Publication Date Title
JP7661478B2 (ja) 可溶性ｎｐｙ２受容体アゴニスト
EP3510044B1 (en) Amylin analogues
AU2011247452B2 (en) Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
JP7821393B2 (ja) Ｎｐｙ２受容体アゴニスト
JP6701075B2 (ja) アミリン類似体
EP3068795B1 (en) Hpyy(1-36) having a beta-homoarginine substitution at position 35
TW201706294A (zh) 胰澱素類似物
EA047394B1 (ru) Агонисты рецептора npy2
EA049057B1 (ru) Растворимые агонисты рецепторов npy2
HK40004264B (en) Amylin analogues

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000